scholarly journals Subcutaneous immunotherapy suppresses Th2 inflammation and induces neutralizing antibodies, but sublingual immunotherapy suppresses airway hyperresponsiveness in grass pollen mouse models for allergic asthma

2018 ◽  
Vol 48 (8) ◽  
pp. 1035-1049 ◽  
Author(s):  
L. Hesse ◽  
U. Brouwer ◽  
A. H. Petersen ◽  
R. Gras ◽  
L. Bosman ◽  
...  
Keyword(s):  
Allergic Asthma ◽  
Mouse Models ◽  
Grass Pollen ◽  
Airway Hyperresponsiveness ◽  
Neutralizing Antibodies ◽  
Sublingual Immunotherapy ◽  
Subcutaneous Immunotherapy ◽  
Th2 Inflammation

scholarly journals High dose vitamin D3 empowers effects of subcutaneous immunotherapy in a grass pollen-driven mouse model of asthma

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Laura Hesse ◽  
N. van Ieperen ◽  
Arjen H. Petersen ◽  
J. N. G. Oude Elberink ◽  
Antoon J. M. van Oosterhout ◽  
...  
Keyword(s):  
Mouse Model ◽  
Grass Pollen ◽  
Airway Hyperresponsiveness ◽  
Allergic Inflammation ◽  
Optimal Dose ◽  
Lavage Fluid ◽  
Subcutaneous Immunotherapy ◽  
High Dose ◽  
Allergen Specific Immunotherapy ◽  
Neutralizing Capacity

AbstractAllergen-specific immunotherapy (AIT) has the potential to provide long-term protection against allergic diseases. However, efficacy of AIT is suboptimal, while application of high doses allergen has safety concerns. The use of adjuvants, like 1,25(OH)2VitD3 (VitD3), can improve efficacy of AIT. We have previously shown that low dose VitD3 can enhance suppression of airway inflammation, but not airway hyperresponsiveness in a grass pollen (GP)-subcutaneous immunotherapy (SCIT) mouse model of allergic asthma. We here aim to determine the optimal dose and formulation of VitD3 for the GP SCIT. GP-sensitized BALBc/ByJ mice received three SCIT injections of VitD3-GP (30, 100, and 300 ng or placebo). Separately, synthetic lipids, SAINT, was added to the VitD3-GP-SCIT formulation (300 nmol) and control groups. Subsequently, mice were challenged with intranasal GP, and airway hyperresponsiveness, GP-specific IgE, -IgG1, and -IgG2a, ear-swelling responses (ESR), eosinophils in broncho-alveolar lavage fluid and lung were measured. VitD3 supplementation of GP-SCIT dose-dependently induced significantly enhanced suppression of spIgE, inflammation and hyperresponsiveness, while neutralizing capacity was improved and ESR were reduced. Addition of VitD3 further decreased Th2 cytokine responses and innate cytokines to allergens in lung tissue by GP-SCIT. However, addition of synthetic lipids to the allergen/VitD3 mixes had no additional effect on VitD3-GP-SCIT. We find a clear, dose dependent effect of VitD3 on GP-SCIT-mediated suppression of allergic inflammation and airway hyperresponsiveness. In contrast, addition of synthetic lipids to the allergen/VitD3 mix had no therapeutic effect. These studies underscore the relevance of VitD3 as an adjuvant to improve clinical efficacy of SCIT treatment regimens.

scholarly journals 1,25(OH)2VitD3 supplementation enhances suppression of grass pollen-induced allergic asthma by subcutaneous and sublingual immunotherapy in a mouse model

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Laura Hesse ◽  
Arjen H. Petersen ◽  
Joanne N. G. Oude Elberink ◽  
Antoon J. M. van Oosterhout ◽  
Martijn C. Nawijn
Keyword(s):  
Mouse Model ◽  
Allergic Asthma ◽  
Grass Pollen ◽  
Sublingual Immunotherapy

scholarly journals Dropouts From Sublingual Immunotherapy and the Transition to Subcutaneous Immunotherapy in House Dust Mite-Sensitized Allergic Rhinitis Patients

2022 ◽  
Vol 2 ◽  
Author(s):  
Huan Chen ◽  
Guo-qing Gong ◽  
Mei Ding ◽  
Xiang Dong ◽  
Yuan-li Sun ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Allergic Asthma ◽  
House Dust ◽  
House Dust Mite ◽  
Sublingual Immunotherapy ◽  
Dropout Rates ◽  
Subcutaneous Immunotherapy ◽  
Transition Rates ◽  
Dust Mite

Purpose: Both subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) are effective in reducing symptoms and medication scores and inducing long-term efficacy in patients with allergic rhinitis (AR). However, SLIT has been associated with poor patient adherence. This study investigates the factors impacting dropout rates from SLIT in house dust mite (HDM)-sensitized AR patients.Methods: A retrospective study was performed to analyze dropout rates and reasons in AR patients receiving Dermatophagoides farinae (Der f) SLIT with a follow-up period of 2 years.Results: A total of 719 HDM-sensitized AR patients received Der f-SLIT. Dropout rates increased with time and most occurred after 1 year of SLIT. By month 24, 654 (91%) patients had discontinued SLIT. The dropout rates by month 24 were 100, 90.1, and 91.1% in children <5 years old, children aged 5–18 years old, and adults ≥ 18 years old, respectively. Combination with allergic asthma and mono- or multi-sensitization to other aeroallergens did not affect the dropout rates. The most common self-reported reasons for dropouts were refusal of continuation, dissatisfaction with the efficacy, transition to SCIT, and adverse effects. Refusal of continuation increased with age, whereas transition to SCIT decreased with age. Ninety-seven cases transitioned from SLIT to SCIT, and the transition rates increased with time. Comorbid allergic asthma did not affect the transition rates. However, multi-sensitization was associated with a slightly higher rate of transition to SCIT. The most common reason for the transition was dissatisfaction with the efficacy (54.6%), which was only reported by patients older than 5 years. For children who began SLIT at younger than 5 years old, the most common reason (81.2%) for transition was age reaching 5 years.Conclusions: HDM-SLIT has a very high dropout rate, which is mainly due to refusal of continuation and dissatisfaction with the efficacy. Transitioning from SLIT to SCIT may help keep these patients on AIT and thus increase adherence and long-term efficacy.

scholarly journals Long-Term Impact of Grass-Pollen (GP) Sublingual Immunotherapy Tablet (SLIT) on Allergic Rhinitis (AR) and on Allergic Asthma (AA) Onset and Progression

2017 ◽  
Vol 20 (9) ◽  
pp. A639-A640
Author(s):  
P Devillier ◽  
M Molimard ◽  
P Demoly ◽  
X Ansolabehere ◽  
I Bardoulat ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Allergic Asthma ◽  
Grass Pollen ◽  
Sublingual Immunotherapy ◽  
Long Term Impact

Efficacy of sublingual immunotherapy tablets in dust mite and pollen allergy

2021 ◽  
Vol 42 (1) ◽  
pp. 36-42 ◽  
Author(s):  
Yuriy Bisyuk ◽  
Ilona DuBuske ◽  
Lawrence M. DuBuske
Keyword(s):  
T Cells ◽  
Comparative Analysis ◽  
Grass Pollen ◽  
Sublingual Immunotherapy ◽  
Pollen Allergy ◽  
Subcutaneous Immunotherapy ◽  
Efficacy And Safety ◽  
Dust Mite ◽  
Timothy Grass Pollen ◽  
New Biomarkers

The latest evidence on the mechanisms, efficacy, and safety of sublingual immunotherapy (SLIT) was reviewed. Interleukin (IL) 35 and IL-35‐producing regulatory T cells were assessed as new biomarkers for SLIT responsiveness. A detailed analysis of clinical studies, including timothy grass pollen, 5-grass pollen, ragweed, and house-dust mite SLIT tablets, was provided, including a comparative analysis of efficacy and safety of SLIT versus subcutaneous immunotherapy.

Safety of sublingual grass pollen immunotherapy after anaphylaxis

2008 ◽  
Vol 123 (6) ◽  
pp. 683-684 ◽  
Author(s):  
J R Nichani ◽  
J de Carpentier
Keyword(s):  
Case Report ◽  
Adverse Events ◽  
Grass Pollen ◽  
Side Effect ◽  
Sublingual Immunotherapy ◽  
Subcutaneous Immunotherapy ◽  
Side Effect Profile ◽  
Fatal Complication ◽  
Discontinuation Of Treatment ◽  
Safe Treatment Option

AbstractAim:To demonstrate that sublingual immunotherapy is a safe treatment option in patients who have previously suffered anaphylaxis when undergoing subcutaneous grass pollen immunotherapy.Case report:We report two patients who developed a systemic anaphylactic reaction following subcutaneous grass pollen immunotherapy, resulting in discontinuation of treatment. Following treatment of the acute anaphylactic episode, both patients were subsequently safely commenced on sublingual grass pollen immunotherapy.Conclusion:Injection immunotherapy has a relatively low risk of severe adverse events, although anaphylaxis is a potentially fatal complication and usually results in termination of the immunotherapy programme. Sublingual immunotherapy has a safer side effect profile than subcutaneous immunotherapy, with no reported cases of anaphylaxis.

scholarly journals Plant Food Allergy Improvement after Grass Pollen Sublingual Immunotherapy: A Case Series

Pathogens ◽  
2021 ◽  
Vol 10 (11) ◽  
pp. 1412
Author(s):  
Fabiana Furci ◽  
Luisa Ricciardi
Keyword(s):  
Food Allergy ◽  
Grass Pollen ◽  
Sublingual Immunotherapy ◽  
Case Series ◽  
Food Allergies ◽  
Subcutaneous Immunotherapy ◽  
Pollen Extract ◽  
Plant Food ◽  
Good Tolerance ◽  
Sublingual Tablet

Background: Cross-reactivity between pollens and plant food has been widely described. Pollen extract subcutaneous immunotherapy in patients with pollens and plant food allergy has been shown to improve tolerance not only to inhalant allergens but also to reduce symptoms in patients with various food allergies. Methods: We retrospectively report our experience with 15 female patients with a positive history for moderate, persistent allergic rhinitis due to grass pollen and oropharyngeal symptoms after ingestion of different plant food. These patients followed a five-grass pollen sublingual tablet immunotherapy for three years in a discontinuous pre-co-seasonal scheme. Results: All 15 patients treated with the 5-grass pollen sublingual tablet immunotherapy, taken once daily for 3 years on a 7-month course, showed improved ocular/nasal symptoms, with a reduction in the use of symptomatic drugs (e.g., nasal corticosteroids and H1 antihistamines). After the first seven-month course of immunotherapy, all patients declared a good tolerance to the intake of fruits and vegetables, and in particular, good tolerance to the offending foods. Conclusions: In conclusion, we have observed improvement of both respiratory and plant food allergies after sublingual immunotherapy (SLIT) with a five-grass pollen tablet.

Sign in / Sign up

Export Citation Format

Share Document